Parul Agarwal
YOU?
Author Swipe
View article: Supplementary Tables 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma
Supplementary Tables 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Open
Supplementary Tables
View article: Supplementary Figure 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma
Supplementary Figure 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Open
Supplementary Figure 1
View article: Data from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma
Data from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Open
Purpose:Borderline resectable pancreatic ductal adenocarcinoma (PDAC) is treated with perioperative chemotherapy and surgical resection with or without stereotactic body radiotherapy (SBRT), but long-term survival is rare. GVAX is a GM-CSF…
View article: Evaluating Treatment Patterns in Bell's Palsy Using Nationwide Employer‐Sponsored Healthcare Claims
Evaluating Treatment Patterns in Bell's Palsy Using Nationwide Employer‐Sponsored Healthcare Claims Open
Objective Professional society guidelines provide clear recommendations regarding the use of high‐dose steroids and/or antiviral therapy for Bell's palsy patients. This study evaluates national trends in the care of Bell's palsy patients a…
View article: Access to affordable daycare and women’s mental health in Rajasthan, India: Evidence from a cluster-randomised social intervention
Access to affordable daycare and women’s mental health in Rajasthan, India: Evidence from a cluster-randomised social intervention Open
ISRCTN clinical trial registry (ISRCTN45369145), registered on 16 May 2016; American Economic Association's registry for randomised controlled trials (AEARCTR-0000774), registered on 15 July 2015.
View article: Data from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Data from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Ten percent of pancreatic neuroendocrine tumors (pNET) are related to inherited syndromes (MEN1, MEN4, VHL, NF1, and TSC). Growing evidence suggests that clinically sporadic pNETs can also harbor germline…
View article: Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Table 3: Stratified analysis of the clinical factors in the unselected cohort (MEN1 and DNA repair genes)
View article: Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Figure 1: Flow diagram showing the type of testing in both the cohorts.
View article: Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Figure 1: Flow diagram showing the type of testing in both the cohorts.
View article: Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Table 1: Details of each P/LP detected in the high-risk cohort along with the high-risk criteria
View article: Data from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Data from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Ten percent of pancreatic neuroendocrine tumors (pNET) are related to inherited syndromes (MEN1, MEN4, VHL, NF1, and TSC). Growing evidence suggests that clinically sporadic pNETs can also harbor germline…
View article: Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Table 2: Variety of genes tested in the unselected cohort (83–86)
View article: Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Table 1: Details of each P/LP detected in the high-risk cohort along with the high-risk criteria
View article: Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Table 3: Stratified analysis of the clinical factors in the unselected cohort (MEN1 and DNA repair genes)
View article: Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Open
Supplementary Table 2: Variety of genes tested in the unselected cohort (83–86)
View article: Figure S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 4. Spaghetti plot of tumor mutation VAF changes with 2 cycles of GAX-CI. To determine the impact of GAX-CI on the allelic frequency of mutations detected in ctDNA, we measured the VAF of these mutations pre-treatment an…
View article: Figure S1 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S1 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 1. Pairwise scatterplots comparing protein and cfDNA biomarkers for Post-treatment time point and % change pre-treatment to post-treatment. To determine the relationship between the different protein and cfDNA biomarker…
View article: Figure S3 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S3 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 3. Post-treatment KRAS and change in KRAS VAF following treatment. To determine whether KRAS VAF following 2 cycles of treatment or the change in KRAS VAF from pre-treatment to after 2 cycles of treatment is correlated …
View article: Figure S2 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S2 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 2. Scatterplots comparing baseline RECIST tumor measurements with baseline cell-free DNA (cfDNA) biomarkers. To determine the relationship between baseline tumor mutational variant allele frequency (VAFs) and total tumo…
View article: Data from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Data from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
The treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) is frequently characterized by significant toxicity and rapid development of resistance to current approved therapies. More reliable biomarkers of response are needed to g…
View article: Figure S1 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S1 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 1. Pairwise scatterplots comparing protein and cfDNA biomarkers for Post-treatment time point and % change pre-treatment to post-treatment. To determine the relationship between the different protein and cfDNA biomarker…
View article: Figure S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 4. Spaghetti plot of tumor mutation VAF changes with 2 cycles of GAX-CI. To determine the impact of GAX-CI on the allelic frequency of mutations detected in ctDNA, we measured the VAF of these mutations pre-treatment an…
View article: Tables S1-S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Tables S1-S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Table S1: Patient demographics. Table S2: Summary of TP53 VAF and KRAS VAF data for patient cohort (N=12). Table S3: Correlation between TP53 VAF, KRAS VAF, or median VAF and CEA and CA19-9 biomarkers using Spearman rank correlation coeffi…
View article: Tables S1-S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Tables S1-S4 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Table S1: Patient demographics. Table S2: Summary of TP53 VAF and KRAS VAF data for patient cohort (N=12). Table S3: Correlation between TP53 VAF, KRAS VAF, or median VAF and CEA and CA19-9 biomarkers using Spearman rank correlation coeffi…
View article: Figure S5 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S5 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 5. Post-treatment Median VAF Predicts Progression-Free Survival. To assess whether Median mutation variant allele fraction (VAF) in cell-free DNA (cfDNA) predicted progression-free survival (PFS) and overall survival (O…
View article: Data from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Data from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
The treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) is frequently characterized by significant toxicity and rapid development of resistance to current approved therapies. More reliable biomarkers of response are needed to g…
View article: Figure S2 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S2 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 2. Scatterplots comparing baseline RECIST tumor measurements with baseline cell-free DNA (cfDNA) biomarkers. To determine the relationship between baseline tumor mutational variant allele frequency (VAFs) and total tumo…
View article: Figure S5 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S5 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 5. Post-treatment Median VAF Predicts Progression-Free Survival. To assess whether Median mutation variant allele fraction (VAF) in cell-free DNA (cfDNA) predicted progression-free survival (PFS) and overall survival (O…
View article: Figure S3 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
Figure S3 from Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Open
Supplemental Figure 3. Post-treatment KRAS and change in KRAS VAF following treatment. To determine whether KRAS VAF following 2 cycles of treatment or the change in KRAS VAF from pre-treatment to after 2 cycles of treatment is correlated …
View article: Cancer beliefs and screening behaviors: The impact of neighborhood and other social determinants of health
Cancer beliefs and screening behaviors: The impact of neighborhood and other social determinants of health Open
Background Beliefs about cancer influence breast and colorectal cancer (CRC) screening behavior. Screening rates for these cancers differ in the contiguous neighborhoods of East Harlem (EH), Central Harlem (CH), and the Upper East Side (UE…